If you are not happy with the results below please do another search
According to GlobalData, more than 190 million people currently live with type 2 diabetes and/or obesity in 7MM, and the numbers will be growing at an annual growth rate (AGR) of 1.35% and 0.57% for type 2 diabetes and obesity, respectively, in the next 10 years.
Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma companies. Will getting rid of management layers fix Bayer?
The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley’s plans to boost earnings at the drugmaker.
The drug, marketed under the name Imdelltra, is part of Amgen’s pipeline of bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body’s immune system can kill the cancer.
“If women aren’t in decision-making roles, then the best decisions won’t always be made,” declared Healthcare Businesswomen’s Association’s (HBA) CEO Mary Stutts. “If our workplaces are not inclusive and representative of our patient populations, health equity will never become a reality.” Stutts opened the HBA’s annual Woman of the Year program with a call to action for the professionals in the room as well as the broader industry. “We all share the moral and ethical responsibility, as well as the financial obligation, to do better. We’re in a new era.”
Following back-to-back approvals in lymphocytic leukemia, Bristol Myers Squibb’s CAR-T therapy Breyanzi on Wednesday won the FDA’s green light for relapsed or refractory follicular lymphoma.
Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational GLP-1/GIP receptor agonist induced strong weight loss in a Phase Ib study.
Eli Lilly said its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients with type 2 diabetes.
J&J looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
The companies announced they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
